Test Statement

Ipsen announces the conclusion of an agreement between its main shareholders representing 52.06% of the capital and 66.15% of the voting rights

ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio

Ipsen to present data across five rare liver diseases at AASLD 2025

Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC

Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s

An update for healthcare professionals and patients on Increlex® (mecasermin) Injection

Ipsen announces sale of Priority Review Voucher for $158m

Ipsen and Medetia join forces to accelerate early research in rare disease

Offering support to those impacted in Turkey & Syria